346 related articles for article (PubMed ID: 30665814)
1. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.
Sundahl N; Vandekerkhove G; Decaestecker K; Meireson A; De Visschere P; Fonteyne V; De Maeseneer D; Reynders D; Goetghebeur E; Van Dorpe J; Verbeke S; Annala M; Brochez L; Van der Eecken K; Wyatt AW; Rottey S; Ost P
Eur Urol; 2019 May; 75(5):707-711. PubMed ID: 30665814
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
[TBL] [Abstract][Full Text] [Related]
3. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Luke JJ; Lemons JM; Karrison TG; Pitroda SP; Melotek JM; Zha Y; Al-Hallaq HA; Arina A; Khodarev NN; Janisch L; Chang P; Patel JD; Fleming GF; Moroney J; Sharma MR; White JR; Ratain MJ; Gajewski TF; Weichselbaum RR; Chmura SJ
J Clin Oncol; 2018 Jun; 36(16):1611-1618. PubMed ID: 29437535
[TBL] [Abstract][Full Text] [Related]
4. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study.
Fukushima H; Kijima T; Fukuda S; Moriyama S; Uehara S; Yasuda Y; Tanaka H; Yoshida S; Yokoyama M; Matsuoka Y; Saito K; Matsubara N; Numao N; Sakai Y; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
Cancer Med; 2020 Nov; 9(22):8355-8363. PubMed ID: 32886446
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.
Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
Li D; He C; Xia Y; Du Y; Zhang J
J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.
Ho AY; Barker CA; Arnold BB; Powell SN; Hu ZI; Gucalp A; Lebron-Zapata L; Wen HY; Kallman C; D'Agnolo A; Zhang Z; Flynn J; Dunn SA; McArthur HL
Cancer; 2020 Feb; 126(4):850-860. PubMed ID: 31747077
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.
Ni J; Zhou Y; Wu L; Ai X; Dong X; Chu Q; Han C; Wang X; Zhu Z
Radiat Oncol; 2021 Sep; 16(1):177. PubMed ID: 34526044
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Varga A; Piha-Paul S; Ott PA; Mehnert JM; Berton-Rigaud D; Morosky A; Yang P; Ruman J; Matei D
Gynecol Oncol; 2019 Feb; 152(2):243-250. PubMed ID: 30522700
[TBL] [Abstract][Full Text] [Related]
12. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Zhang T; Harrison MR; O'Donnell PH; Alva AS; Hahn NM; Appleman LJ; Cetnar J; Burke JM; Fleming MT; Milowsky MI; Mortazavi A; Shore N; Sonpavde GP; Schmidt EV; Bitman B; Munugalavadla V; Izumi R; Patel P; Staats J; Chan C; Weinhold KJ; George DJ
Cancer; 2020 Oct; 126(20):4485-4497. PubMed ID: 32757302
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for the treatment of bladder cancer.
Sundahl N; Rottey S; De Maeseneer D; Ost P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
[TBL] [Abstract][Full Text] [Related]
15. A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
Cammaert T; Decaestecker K; Sundahl N; Rottey S; Devreese KMJ
Ann Hematol; 2018 Mar; 97(3):545-546. PubMed ID: 29130135
[No Abstract] [Full Text] [Related]
16. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
[TBL] [Abstract][Full Text] [Related]
17. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in medical therapy for metastatic urothelial cancer.
Yuasa T; Urakami S; Yonese J
Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
20. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J
J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
